Palvella Therapeutics (PVLA) Capital Expenditures Growth (5y) (2019 - 2023)
Palvella Therapeutics (PVLA) Capital Expenditures Growth (5y) (2019 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.89 Bn | 1.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -15.13% |
| Sep 30, 2023 | -26.65% |
| Jun 30, 2023 | -29.84% |
| Mar 31, 2023 | -35.01% |
| Dec 31, 2022 | 4.28% |
| Sep 30, 2022 | -40.19% |
| Jun 30, 2022 | -1.05% |
| Mar 31, 2022 | 16.79% |
| Dec 31, 2021 | 7.58% |
| Sep 30, 2021 | 12.06% |
| Jun 30, 2021 | 32.21% |
| Mar 31, 2021 | -16.24% |
| Dec 31, 2020 | 10.46% |
| Sep 30, 2020 | -44.54% |
| Jun 30, 2020 | 99.42% |
| Mar 31, 2020 | 116.36% |
| Sep 30, 2019 | 74.57% |
| Jun 30, 2019 | 185.01% |
| Mar 31, 2019 | 132.84% |